Endotheliopathy and VWF-ADAMTS13 axis dysfunction in VEXAS thrombogenicity.

VEXAS syndrome causes endothelial activation and endotheliopathy, leading to a 52.5% thrombotic event rate and significant alterations in VWF and coagulation factors.

• Why it matters: Understanding the mechanisms behind VEXAS-associated hypercoagulability is crucial for developing targeted treatments for this autoinflammatory disorder with high thrombosis risk.
• What they did: Researchers analyzed plasma from 40 VEXAS patients with UBA1 variants, measuring VWF, FVIII, angiopoietin II, VCAM-1, thrombomodulin, and thrombin generation, comparing these to controls.
• The result: Findings reveal endothelial activation, increased VWF multimers, elevated FVIII, and hypercoagulability markers, suggesting potential therapeutic targets within the EC and VWF-ADAMTS13 pathways.